According to the research report titled ‘Global Oncology/Cancer Blockbuster Drugs Market Research Report 2019 – 2025’, available with MarketStudyReport, worldwide oncology/cancer blockbuster drugs market is projected to grow considerably, with the global 27 cancer blockbuster drugs market value to surpass USD 120 by the end of the forecast period.
 

Global oncology/cancer blockbuster drugs market growth can be credited to rising cases of cancer, booming elderly population, and increasing government expenditure on healthcare. Moreover, the industry prognosis is expected to be bolstered by rising cognizance of the disease and the widespread availability of cancer-treating medications.
 

Request sample copy of this report: https://www.marketstudyreport.com/request-a-sample/1868453/
 

Apart from drivers and opportunities, the literature also discusses current and future challenges, as well as potential remedies. It also considers the history of market augmentation, as well as the current business landscape to produce reliable estimates for growth rate, size, revenue share, and other key metrics.
 

The research provides the most up-to-date industry information on the current market condition and prospects for the market. Otcontains historical data from 2015 to 2018, and projections till 2025.
 

A detailed examination of the top 27 medications currently available in global oncology/cancer blockbuster drugs market is also given. The report studies top drugs, namely, Imbruvica, Revlimid, Pomalyst/Imnovid, Keytruda, Herceptin, Avastin, MabThera/Rituxan, Perjeta, Opdivo, Sprycel, Ibrance, Zytiga, Tagrisso, Darzalex, Xtandi, Jakafi/Jakavi, Yervoy, Alimta, Gleevec/Glivec, Velcade, Tasigna, Xgeva, Afinitor/Votubia, Neulasta, Exjade Jaden, Sandostatin, and Faslodex. It also reveals the revenue generated by each drug and the highest market share captured throughout the assessment period.
 

Moving ahead with the analysis, the report provides an in-depth analysis of the competitive landscape by concentrating on the performance of the industry's leading players. Prominent firms impacting the marketplace with their products, services, and continuous developments are AstraZeneca plc, Celgene, Novartis, Amgen, Roche, Bristol-Myers Squibb, Pfizer Inc., Eli Lilly and Company, Merck, and Johnson & Johnson.